Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-19 4:09 pm Purchase | 2026-05-12 | 13G | C4 THERAPEUTICS INC CCCC | Squadron Master Fund LP | 5,550,000 5.000% | 5,550,000 (New Position) | Filing History |
| 2026-05-15 4:20 pm Sale | 2026-03-31 | 13G | C4 THERAPEUTICS INC CCCC | Point72 Asset Management, L.P. | 169,096 0.200% | -22,478,551 (-99.25%) | Filing History |
| 2026-05-15 08:10 am Purchase | 2026-03-31 | 13G | C4 THERAPEUTICS INC CCCC | Sirenia Capital Management LP | 23,505,000 9.900% | 23,505,000 (New Position) | Filing History |
| 2026-04-22 5:27 pm Sale | 2026-03-31 | 13G | C4 THERAPEUTICS INC CCCC | WASATCH ADVISORS LP | 4,581,761 4.700% | -270,980 (-5.58%) | Filing History |
| 2026-02-17 6:18 pm Sale | 2025-12-31 | 13G | C4 THERAPEUTICS INC CCCC | ORBIMED ADVISORS LLC | 883,534 1.000% | -2,684,812 (-75.24%) | Filing History |
| 2026-02-17 1:45 pm Purchase | 2025-12-31 | 13G | C4 THERAPEUTICS INC CCCC | Lynx1 Capital Management LP | 7,098,133 7.300% | 217,606 (+3.16%) | Filing History |
| 2026-02-12 5:02 pm Purchase | 2025-12-31 | 13G | C4 THERAPEUTICS INC CCCC | Soleus Capital Master Fund, L.P. | 10,361,860 9.990% | 3,757,864 (+56.90%) | Filing History |
| 2026-02-11 12:58 pm Purchase | 2025-12-31 | 13G | C4 THERAPEUTICS INC CCCC | MORGAN STANLEY MS | 8,974,191 9.300% | 4,223,808 (+88.92%) | Filing History |
| 2025-11-14 6:08 pm Sale | 2025-09-30 | 13G | C4 THERAPEUTICS INC CCCC | ORBIMED ADVISORS LLC | 3,568,346 5.000% | -1,087,254 (-23.35%) | Filing History |
| 2025-11-13 5:33 pm Sale | 2025-09-30 | 13G | C4 THERAPEUTICS INC CCCC | WASATCH ADVISORS LP | 4,852,741 6.800% | -2,620,591 (-35.07%) | Filing History |
| 2025-10-24 4:30 pm Purchase | 2025-10-17 | 13G | C4 THERAPEUTICS INC CCCC | BCLS II Equity Opportunities, LP | 6,060,000 6.250% | 6,060,000 (New Position) | Filing History |
| 2025-10-24 4:13 pm Purchase | 2025-10-17 | 13G | C4 THERAPEUTICS INC CCCC | RA Capital Management, L.P. | 9,441,256 9.900% | 9,441,256 (New Position) | Filing History |
| 2025-10-20 5:58 pm Purchase | 2025-10-17 | 13G | C4 THERAPEUTICS INC CCCC | Point72 Asset Management, L.P. | 22,647,647 9.900% | 21,333,900 (+1623.90%) | Filing History |
| 2025-08-07 12:50 pm Purchase | 2025-06-30 | 13G | C4 THERAPEUTICS INC CCCC | MORGAN STANLEY MS | 4,750,383 6.700% | 921,573 (+24.07%) | Filing History |
| 2025-07-16 7:02 pm Sale | 2025-06-30 | 13G | C4 THERAPEUTICS INC CCCC | BlackRock Inc. BLK | 1,756,613 2.500% | -3,134,766 (-64.09%) | Filing History |
| 2025-05-15 8:09 pm Purchase | 2025-03-31 | 13G | C4 THERAPEUTICS INC CCCC | ORBIMED ADVISORS LLC | 4,655,600 6.600% | 1,729,700 (+59.12%) | Filing History |
| 2025-05-15 4:52 pm Sale | 2025-03-31 | 13G | C4 THERAPEUTICS INC CCCC | RA Capital Management, L.P. | 0 0.000% | -4,878,000 (Position Closed) | Filing History |
| 2025-05-07 1:39 pm Purchase | 2025-04-30 | 13G | C4 THERAPEUTICS INC CCCC | WASATCH ADVISORS LP | 7,473,332 10.500% | 1,956,614 (+35.47%) | Filing History |
| 2025-02-03 1:59 pm Purchase | 2024-12-31 | 13G | C4 THERAPEUTICS INC CCCC | MORGAN STANLEY MS | 3,828,810 5.400% | 3,828,810 (New Position) | Filing History |
| 2024-11-14 7:53 pm Sale | 2024-09-30 | 13G | C4 THERAPEUTICS INC CCCC | Point72 Asset Management, L.P. | 1,313,747 1.900% | -1,362,949 (-50.92%) | Filing History |